Novo Nordisk ( NVO ) has multiple, strong upcoming, positive catalysts, all related to its popular GLP-1 weight-loss drugs, Ozempic and Wegovy. Meanwhile, given the firm's strong growth outlook, the valuation of NVO stock is attractive at this point. Consequently, I recommendAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my ow ...

Novo Nordisk (NVO) closed the most recent trading day at $136.66, moving +1.06% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.75%. Elsewhere, the Dow saw an upswing of 0.58%, while the tech-heavy Nasdaq appreciated by 1%.Heading into today, shares of the drugmaker had gained 0.6% over the past month, lagging the Medical sector's gain of 3.55% and the S&P 500's gain of 4.03% in that time.The investment community will be paying close attention to the ...

Novo Nordisk’s (NVO) oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in response to the positive news, shares of other drugmakers — Eli Lilly (LLY) , Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) — whose oral pills for obesity are in mid-to-late-stage development also rose on Wednesday.   Drugmakers are competing fiercely to enter the obesity market due to the huge untappe ...

Shares of Novo Nordisk (NVO) gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill, amycretin, at the European Association for the Study of Diabetes meeting in Madrid.NVO’s Amycretin Shows Efficacy Superior to Wegovy in StudyNovo Nordisk’s oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection for chronic weight management, Wegovy (semaglutide), in the phase I stud ...

The biotech sector represents companies that use biological processes to develop new medicines and treatments. These firms range from small startups to large pharmaceutical giants. Biotech stocks are shares in these innovative companies that trade on public exchanges. The sector is known for its potential to revolutionize healthcare and generate significant returns. However, it’s also associated with high risk due to the complex nature of drug development.Investing in biotech stocks can offer exciting oppor ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Novo Nordisk (NVO) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Novo Nordisk currently has an average b ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this drugmaker have returned +1.6% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Novo Nordisk belongs, has gained 2.1% over this period. Now the key question is: Where could the stock be headed in the near term?Although media repor ...

VANCOUVER, British Columbia, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise that the Company’s Executive Co-Chairman and Acting Chief Executive Officer Mike Spreadborough will present at the Resources Rising Stars Gold Coast Investor Conference, being held on Tuesday 3rd and Wednesday 4th September 2024. Mike will provide an update on the Company’s current and future exploration programs across Novo’s highly prospective ...

This competitive showdown just saw one of the players hit a couple of bumps.Eli Lilly (LLY 2.11%) and Novo Nordisk (NVO 1.19%) are big pharma peers. They're also each other's biggest rivals, especially in the all-important market for weight-loss drugs, in which both are currently highly successful.Right now, there are a few reasons to believe that Eli Lilly has the upper hand in this competitive clash. Those reasons support buying its stock, assuming you don't want to invest in both companies. Here are thre ...

The addressable market for the treatments could potentially contract significantly.Novo Nordisk's (NVO 2.26%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the context of obesity. But, if some new information holds true, the company could soon see its presence in both of those markets take a hit.Here's what was just discovered and why it matters.This potential side effect needs urgent invest ...